|Bid||230.06 x 900|
|Ask||230.18 x 800|
|Day's range||228.24 - 230.83|
|52-week range||129.21 - 275.87|
|Beta (5Y monthly)||0.25|
|PE ratio (TTM)||34.57|
|Earnings date||26 Oct 2021|
|Forward dividend & yield||3.40 (1.47%)|
|Ex-dividend date||12 Aug 2021|
|1y target est||262.24|
FDA revises Lilly's (LLY) EUA for COVID-19 antibody cocktail, bamlanivimab and etesevimab, for post-exposure prophylaxis for COVID-19.
AbbVie (ABBV) buys rights to Regenexbio's gene therapy candidate for chronic retinal diseases. Lilly (LLY) will supply additional doses of its COVID-19 antibody medicine to the U.S. government.
Regeneron (REGN) is set to supply an additional 1.4 million doses of its antibody cocktail for COVID-19, REGEN-COV while Lilly (LLY) will supply 388,000 doses of its COVID-19 antibody medicine, etesevimab to the U.S. government.